MedTrace Logo

Diazepam Trial in GAD65 Associated Epilepsy

NCT05361447 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2025-03-06

No results posted yet for this study

Summary

The purpose of this study is to determine whether diazepam reduces the frequency of seizures in GAD65 antibody associated epilepsy.

Conditions

  • GAD 65 Antibody-associated Epilepsy

Interventions

DRUG

Diazepam

5 mg twice daily oral for 1 week and then increase to 10 mg twice daily oral

Sponsors & Collaborators

Principal Investigators

  • Kelsey Smith, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-11
Primary Completion
2024-12-13
Completion
2024-12-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05361447 on ClinicalTrials.gov